Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,123.48 +44.62 (+0.55%) Bitcoin USD
63,918.06 +684.68 (+1.08%) CMC Crypto 200
1,378.56 -17.98 (-1.29%)
VRTX Jan 2025 330.000 call
- Zacks
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.
- Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.
- Zacks
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
